Department of Ophthalmology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Pharmacology. 2013;92(5-6):310-4. doi: 10.1159/000356407. Epub 2013 Dec 4.
BACKGROUND/AIMS: Bevacizumab (Avastin), an anti-vascular endothelial growth factor drug, has been successfully used in the recent years to treat ocular pathologies, mostly by intravitreal administration. The aim of the current study was to assess the off-label topical use of high-dose bevacizumab for the treatment of corneal neovascularization.
Seventeen eyes of 17 patients with corneal neovascularization secondary to various pathologies were included. The patients were treated with topical bevacizumab (25 mg/ml) 4 times daily for 2 weeks. The following parameters were evaluated at baseline and on days 3, 7 and 14: visual acuity, slit-lamp examination, intraocular pressure, heart rate and blood pressure. Color photos were obtained at baseline and on day 14.
Eleven eyes (65%) demonstrated regression of corneal neovascularization and/or clearing of corneal opacification. Adverse ocular events were mild and transient, and included eyelid swelling/chalazion and superficial punctate keratitis.
Treatment with high-dose topical bevacizumab (25 mg/ml) was effective for corneal neovascularization in nearly two thirds of the eyes treated. Adverse ocular side effects were mild and transient.
背景/目的：贝伐单抗（阿瓦斯汀）是一种抗血管内皮生长因子药物，近年来已成功用于治疗眼部疾病，主要通过玻璃体内给药。本研究旨在评估高剂量贝伐单抗局部外用治疗角膜新生血管的疗效。
纳入了 17 例由各种病因引起的角膜新生血管的患者共 17 只眼。患者接受每日 4 次局部贝伐单抗（25mg/ml）治疗 2 周。在基线和第 3、7、14 天评估以下参数：视力、裂隙灯检查、眼压、心率和血压。在基线和第 14 天拍摄彩色照片。
11 只眼（65%）的角膜新生血管消退和/或角膜混浊减轻。眼部不良事件轻微且短暂，包括眼睑肿胀/霰粒肿和浅层点状角膜炎。
高剂量局部贝伐单抗（25mg/ml）治疗对近三分之二的治疗眼的角膜新生血管有效。眼部不良反应轻微且短暂。
